These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

600 related articles for article (PubMed ID: 28087148)

  • 1. Immunogenicity differences of a 15-valent pneumococcal polysaccharide conjugate vaccine (PCV15) based on vaccine dose, route of immunization and mouse strain.
    Caro-Aguilar I; Indrawati L; Kaufhold RM; Gaunt C; Zhang Y; Nawrocki DK; Giovarelli C; Winters MA; Smith WJ; Heinrichs J; Skinner JM
    Vaccine; 2017 Feb; 35(6):865-872. PubMed ID: 28087148
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity Comparison of a Next Generation Pneumococcal Conjugate Vaccine in Animal Models and Human Infants.
    Xie J; Zhang Y; Caro-Aguilar I; Indrawati L; Smith WJ; Giovarelli C; Winters MA; MacNair J; He J; Abeygunawardana C; Musey L; Kosinski M; Skinner JM
    Pediatr Infect Dis J; 2020 Jan; 39(1):70-77. PubMed ID: 31725555
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Methotrexate reduces vaccine-specific immunoglobulin levels but not numbers of circulating antibody-producing B cells in rheumatoid arthritis after vaccination with a conjugate pneumococcal vaccine.
    Kapetanovic MC; Nagel J; Nordström I; Saxne T; Geborek P; Rudin A
    Vaccine; 2017 Feb; 35(6):903-908. PubMed ID: 28081972
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pre-clinical evaluation of a 15-valent pneumococcal conjugate vaccine (PCV15-CRM197) in an infant-rhesus monkey immunogenicity model.
    Skinner JM; Indrawati L; Cannon J; Blue J; Winters M; Macnair J; Pujar N; Manger W; Zhang Y; Antonello J; Shiver J; Caulfield M; Heinrichs JH
    Vaccine; 2011 Nov; 29(48):8870-6. PubMed ID: 21964055
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine compared to 13-valent pneumococcal conjugate vaccine in adults ≥65 years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine.
    Peterson JT; Stacey HL; MacNair JE; Li J; Hartzel JS; Sterling TM; Benner P; Tamms GM; Musey LK
    Hum Vaccin Immunother; 2019; 15(3):540-548. PubMed ID: 30427749
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A dose ranging study of 2 different formulations of 15-valent pneumococcal conjugate vaccine (PCV15) in healthy infants.
    Rupp R; Hurley D; Grayson S; Li J; Nolan K; McFetridge RD; Hartzel J; Abeygunawardana C; Winters M; Pujar H; Benner P; Musey L
    Hum Vaccin Immunother; 2019; 15(3):549-559. PubMed ID: 30689507
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine (PCV-15) compared to PCV-13 in healthy older adults.
    Stacey HL; Rosen J; Peterson JT; Williams-Diaz A; Gakhar V; Sterling TM; Acosta CJ; Nolan KM; Li J; Pedley A; Benner P; Abeygunawardana C; Kosinski M; Smith WJ; Pujar H; Musey LK
    Hum Vaccin Immunother; 2019; 15(3):530-539. PubMed ID: 30648919
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pneumococcal polysaccharide vaccination administered early after neurotrauma or neurosurgery.
    Hedberg AL; Pauksens K; Enblad P; Söderberg J; Johansson B; Käyhty H; Sjölin J
    Vaccine; 2017 Feb; 35(6):909-915. PubMed ID: 28069358
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety, tolerability, and immunogenicity of 15-valent pneumococcal conjugate vaccine in healthy adults.
    McFetridge R; Meulen AS; Folkerth SD; Hoekstra JA; Dallas M; Hoover PA; Marchese RD; Zacholski DM; Watson WJ; Stek JE; Hartzel JS; Musey LK
    Vaccine; 2015 Jun; 33(24):2793-9. PubMed ID: 25913828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine.
    Jackson LA; Gurtman A; Rice K; Pauksens K; Greenberg RN; Jones TR; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
    Vaccine; 2013 Aug; 31(35):3585-93. PubMed ID: 23688527
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative evaluation of a newly developed 13-valent pneumococcal conjugate vaccine in a mouse model.
    Park C; Kwon EY; Choi SM; Cho SY; Byun JH; Park JY; Lee DG; Kang JH; Shin J; Kim H
    Hum Vaccin Immunother; 2017 May; 13(5):1169-1176. PubMed ID: 27960627
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults.
    Jackson LA; Gurtman A; van Cleeff M; Jansen KU; Jayawardene D; Devlin C; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
    Vaccine; 2013 Aug; 31(35):3577-84. PubMed ID: 23688526
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of initial vaccination with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine on anti-pneumococcal responses following subsequent pneumococcal vaccination in adults 50 years and older.
    Jackson LA; Gurtman A; van Cleeff M; Frenck RW; Treanor J; Jansen KU; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
    Vaccine; 2013 Aug; 31(35):3594-602. PubMed ID: 23688525
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunologic priming of young children by pneumococcal glycoprotein conjugate, but not polysaccharide, vaccines.
    O'Brien KL; Steinhoff MC; Edwards K; Keyserling H; Thoms ML; Madore D
    Pediatr Infect Dis J; 1996 May; 15(5):425-30. PubMed ID: 8724065
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity and safety of the 13-valent Pneumococcal Conjugate vaccine in 23-valent pneumococcal polysaccharide vaccine-naive and pre-immunized patients under treatment with chronic haemodialysis: a longitudinal quasi-experimental phase IV study.
    Vandecasteele SJ; De Bacquer D; Caluwe R; Ombelet S; Van Vlem B
    Clin Microbiol Infect; 2018 Jan; 24(1):65-71. PubMed ID: 28559003
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functional anti-polysaccharide IgG titres induced by unadjuvanted pneumococcal-conjugate vaccine when delivered by microprojection-based skin patch.
    Pearson FE; Muller DA; Roalfe L; Zancolli M; Goldblatt D; Kendall MA
    Vaccine; 2015 Nov; 33(48):6675-83. PubMed ID: 26518398
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of previous vaccination with pneumococcal conjugate vaccine on pneumococcal polysaccharide vaccine antibody responses.
    Schaballie H; Wuyts G; Dillaerts D; Frans G; Moens L; Proesmans M; Vermeulen F; De Boeck K; Meyts I; Bossuyt X
    Clin Exp Immunol; 2016 Aug; 185(2):180-9. PubMed ID: 26939935
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Conjugation of PspA4Pro with Capsular Streptococcus pneumoniae Polysaccharide Serotype 14 Does Not Reduce the Induction of Cross-Reactive Antibodies.
    da Silva MA; Converso TR; Gonçalves VM; Leite LCC; Tanizaki MM; Barazzone GC
    Clin Vaccine Immunol; 2017 Aug; 24(8):. PubMed ID: 28637805
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of 5-valent conjugate pneumococcal protein A - Capsular polysaccharide pneumococcal vaccine against invasive pneumococcal disease.
    Meng C; Lin H; Huang J; Wang H; Cai Q; Fang L; Guo Y
    Microb Pathog; 2009 Sep; 47(3):151-6. PubMed ID: 19467319
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pneumococcal conjugate vaccine triggers a better immune response than pneumococcal polysaccharide vaccine in patients with chronic lymphocytic leukemia A randomized study by the Swedish CLL group.
    Svensson T; Kättström M; Hammarlund Y; Roth D; Andersson PO; Svensson M; Nilsson I; Rombo L; Cherif H; Kimby E
    Vaccine; 2018 Jun; 36(25):3701-3707. PubMed ID: 29748028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.